HR 1476119th CongressIntroduced

PLASMA Act

Standard Summary
Balanced plain-English summary

The PLASMA Act amends Medicare's manufacturer discount program to phase in discounts for plasma-derived products, which are biological products derived from human blood or plasma.

Key Points

  • 1Establishes a phase-in schedule for plasma-derived products under Medicare Part D manufacturer discount program
  • 2Sets specified discount percentages that decrease over time (99% in 2026 to 90% by 2030 for most beneficiaries)
  • 3Provides different discount rates for beneficiaries who have vs. haven't met out-of-pocket thresholds
  • 4Applies to plasma-derived products marketed as of August 16, 2022
  • 5Excludes certain drugs dispensed to LIS beneficiaries and specified small manufacturers
  • 6Applies to years 2026 and subsequent

Impact Areas

Medicare Part D beneficiariesManufacturers of plasma-derived productsPharmaceutical industryMedicare prescription drug program costs
Generated by kwaipilot/kat-coder-pro:freeNov 19, 2025